News & Events

2004 Press Releases


San Jose, Calif. - November 2, 2004 - Sertanty, Inc., a leading provider of drug discovery cheminformatics products and services, and CTC Laboratory Systems Corporation (CTCLS), a leading distributor and system integrator of state-of-the-art computer systems and software in Japan, announced today the signing of two distribution agreements for Sertanty's software, databases, and virtual screening (eScreenTM) services. Sertanty, Inc. will provide its latest version software and database releases to CTCLS for sales and marketing directly to pharmaceutical, biotech, and discovery products industries throughout Japan. Additionally, Sertanty and CTCLS will work together to supply clients in Japan with virtual eScreening services, which involve filtering and prioritizing compounds for their ability to bind Kinase and other druggable targets. Front-line support will be provided through the CTCLS offices in Tokyo, with back-line support provided through the Sertanty corporate offices in San Jose, California.

Dr. Steven Muskal, CEO of Sertanty, said, "We are very excited to welcome the world class team at CTCLS into our global sales and support effort. We look forward to increasing our base of users for Sertanty's software, content, and eScreen services throughout Japan."

Mr. Taizo Watanabe, President of CTCLS, said, "Sertanty's software platform, databases, and eScreenTM services are a key addition to the range of technology products and services that our customers in Japan demand. We are excited about bringing these offerings to our customers and satisfying the demand there for increasing the productivity and reliability of knowledge-directed drug discovery."

CTC Laboratory Systems Corporation (Tokyo, Japan), a subsidiary of ITOCHU TECHNO-SCIENCE Corporation, is Japan's leading provider of total information technology solutions for pharmaceutical, chemical, and food processing industries, as well as life sciences research institutions. Additional information on CTCLS can be found at Sertanty, Inc., is headquartered in San Jose, California with sales and support in Boston, Massachusetts. Sertanty provides knowledge-based software, chemistry and Kinase family structureactivity knowledgebases, and collaborative services that accelerate the workflows associated with discovering and evolving novel, medicinally relevant compositions of matter. For information on the company, see